Patent Assignment
Reel/Frame 067718/0834
Corrective Assignment to Correct the the Attorney Docket No. from P-588788-Us to P-566450-US15NCIP, P-566450-US15N; P566450-US15D Previously Recorded at Reel: 67259 Frame: 528. Assignor(S) Hereby Confirms the Assignment.
Recorded: 2024-06-11
Pages: 16
Assignor
HUMANIGEN, INC.
Executed: 2024-03-13
Assignee
TARAN THERAPEUTICS, INC.
5 HAINES COVE DRIVE, SUITE 2, TOMS RIVER, NEW JERSEY, 08753-6810
Covered Properties
(3)
Methods of Treating Immunotherapy-Related Toxicity Using a Gm-Csf Antagonist
Application:
17/234,779 →
Publication:
US 2021/0322547
Methods of Treating Immunotherapy-Related Toxicity Using Lenzilumab
Application:
17/274,167 →
Publication:
US 2021/0290677
Methods of Treating Immunotherapy-Related Toxicity Using a Gm-Csf Antagonist
Application:
17/378,629 →
Publication:
US 2022/0025034
Related Assignments
(4)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 17, 2021
From: DURRANT, CAMERON; CHAPPELL, DALE
To: HUMANIGEN, INC.
Reel/Frame 056580/0942 →
Assignment of Assignor's Interest
Dec 15, 2021
From: DURRANT, CAMERON; CHAPPELL, DALE
To: HUMANIGEN, INC.
Reel/Frame 058402/0943 →
Assignment of Assignor's Interest
Dec 20, 2021
From: DURRANT, CAMERON; CHAPPELL, DALE
To: HUMANIGEN, INC.
Reel/Frame 058437/0351 →
Assignment of Assignor's Interest
Apr 29, 2024
From: HUMANIGEN, INC.
To: TARAN THERAPEUTICS, INC.
Reel/Frame 067259/0528 →